Kenvue Inc. (NYSE:KVUE), a leading bio-tech company, received a consensus analyst recommendation of 'Hold'. Its quarterly cash
dividend increased while stock prices and price targets fluctuated, with Deutsche Bank lowering the target to $23.00 and Citigroup to $20.00.
Johnson & Johnson plans to sell its remaining stake in the company.
Commercial movements included large purchases and sales of Kenvue stock by investment groups and banks such as Quadrature Capital Ltd, Capital World Investors, Clearbridge Investments LLC, Natixis, Swiss National Bank, and JPMorgan Chase & Co. Kenvue's performance came under criticism for its 'woeful' and 'worst-in-class' growth. However, despite soft earnings, some perceive strong fundamentals underlying Kenvue's profile. Legal proceedings saw J&J and Kenvue required to pay $45 million over a baby powder lawsuit. For the first quarter 2024, earnings aligned with
analyst EPS projections. Furthermore, multiple subsequent large-scale acquisitions of Kenvue shares were reported, alongside numerous layoff announcements spanning 2024. Finally, Kenvue's first quarter 2024 earnings showed a quarterly cash dividend declaration, and revenues that beat expectations, but lagging EPS.
Kenvue KVUE News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sun, 28 Jul 2024 15:59:52 GMT -
Rating 3
- Innovation -2
- Information 7
- Rumor -4
